A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Comparative Clinical Study to Evaluate the Efficacy and Safety of OLNP-06 versus Placebo in Subjects with Functional Dyspepsia
- 11 December 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Dietary Supplements
- Vol. 19 (2) , 226-237
Abstract
OLNP-06 is ginger extract product standardized to higher amount of total gingerols formulated with proprietary Aqueosome technology. The safety and efficacy of OLNP-06 were evaluated in a randomized, double blind, placebo controlled, parallel group comparative clinical study in subjects with functional dyspepsia (FD). Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. Fifty subjects aged between 18 and 55 years suffering from FD as per ROME III criteria were enrolled into the study. They were randomized into two treatment groups, one group received OLNP-06, 200 mg twice daily and other group received placebo 200 mg twice daily. The primary efficacy end point was global assessment of overall treatment efficacy (OTE). Secondary efficacy endpoints were elimination rate of three major symptoms (postprandial fullness, upper abdominal bloating and early satiation) and elimination rate for each individual symptom scores. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of OLNP-06. Out of 50 subjects, 48subjects completed the study. Total 79% of the subjects receiving OLNP-06 and 21% of the subjects receiving placebo (p < .05) were classified as responders according to the assessment of OTE. Elimination rate (score 0) of postprandial fullness, upper abdominal bloating and early satiation was 64% in subjects receiving ONLP-06 compared with 13% in the placebo group (p < .05). OLNP-06 was found to be safe and well tolerated as there was no incidence of treatment-related AE’s. Supplementation of OLNP-06 for 4 weeks significantly reduced dyspeptic symptoms in subjects suffering from FD. Trial Registration: Clinical Trial Registry-India, CTRI/2019/09/021019, Registered on 2 Sep 2019.Keywords
This publication has 19 references indexed in Scilit:
- Review article: current treatment options and management of functional dyspepsiaAlimentary Pharmacology & Therapeutics, 2012
- Treatment of functional dyspepsia with sertraline: A double-blind randomized placebo-controlled pilot studyWorld Journal of Gastroenterology, 2012
- A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsiaGut, 2011
- Asian consensus report on functional dyspepsiaJournal of Gastroenterology and Hepatology, 2011
- Functional Dyspepsia Impacts Absenteeism and Direct and Indirect CostsClinical Gastroenterology and Hepatology, 2010
- Effects of ginger on gastric emptying and motility in healthy humansEuropean Journal of Gastroenterology & Hepatology, 2008
- The Functional Gastrointestinal Disorders and the Rome III ProcessGastroenterology, 2006
- Functional Gastroduodenal DisordersGastroenterology, 2006
- American Gastroenterological Association Technical Review on the Evaluation of DyspepsiaGastroenterology, 2005
- A population‐based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster samplingAlimentary Pharmacology & Therapeutics, 2004